Intranasal Droplets and Sprays Could Help Tackle SARS-CoV-2 Researchers from Freie Universität Berlin and the University of Bern have published the results of a groundbreaking study from Aug 10, 2021
SARS-CoV-2 vaccine candidates developed in this project offer three important advantages over most licensed vaccines and others still in development. First, vaccine candidates contain the entire viral buildup and are not limited to the viral spike protein. Second, vaccine administration is needle-free. Third, vaccines could be administered intranasally to induce immune responses at the site of infection.